These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 9240732

  • 1. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
    Heikkinen JE, Selander KS, Laitinen K, Arnala I, Väänänen HK.
    J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
    [Abstract] [Full Text] [Related]

  • 2. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K, Probone Study Group.
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [Abstract] [Full Text] [Related]

  • 3. Bisphosphonates clodronate and etidronate in the prevention of ovariectomy-induced osteopenia in growing rats.
    Lepola VT, Kippo K, Hannuniemi R, Laurén L, Virtamo T, Osterman T, Jalovaara P, Sellman R, Väänänen HK.
    J Bone Miner Res; 1996 Oct; 11(10):1508-17. PubMed ID: 8889851
    [Abstract] [Full Text] [Related]

  • 4. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL, Loft AG, Møller N, Weeke J, Eriksen EF, Mosekilde L, Charles P.
    J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
    [Abstract] [Full Text] [Related]

  • 5. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.
    Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S.
    J Bone Miner Res; 1994 Nov; 9(11):1833-7. PubMed ID: 7863833
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women.
    Gnudi S, Lisi L, Fini M, Malavolta N.
    Int J Tissue React; 2001 Nov; 23(1):33-7. PubMed ID: 11392061
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP.
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [Abstract] [Full Text] [Related]

  • 12. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ.
    N Engl J Med; 2002 Feb 28; 346(9):653-61. PubMed ID: 11870242
    [Abstract] [Full Text] [Related]

  • 13. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K, Brandsaeter B, Wiencke K, Bjøro T, Godang K, Bollerslev J, Schrumpf E.
    Scand J Gastroenterol; 2003 Mar 28; 38(3):320-7. PubMed ID: 12737449
    [Abstract] [Full Text] [Related]

  • 14. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 15. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, Ernst TF, Wenderoth D.
    Climacteric; 2005 Sep 17; 8(3):251-62. PubMed ID: 16390757
    [Abstract] [Full Text] [Related]

  • 16. [A one-year prospective study of disodium etidronate versus 17 beta estradiol in the prevention of postmenopausal osteoporosis].
    Chaouat D, Belange G, Danan S, De Vernejoul MC, Faures Quenet B, Chaouat Y.
    Rev Rhum Ed Fr; 1993 May 17; 60(5):353-8. PubMed ID: 8167642
    [Abstract] [Full Text] [Related]

  • 17. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.
    J Bone Miner Res; 2005 Jun 17; 20(6):962-70. PubMed ID: 15883636
    [Abstract] [Full Text] [Related]

  • 18. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy.
    Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, Massoni C, Cristallini S.
    J Bone Miner Res; 1995 May 17; 10(5):697-703. PubMed ID: 7639104
    [Abstract] [Full Text] [Related]

  • 19. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
    Cosman F, Nieves J, Shen V, Lindsay R.
    J Bone Miner Res; 1995 Apr 17; 10(4):594-600. PubMed ID: 7610930
    [Abstract] [Full Text] [Related]

  • 20. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ, Im JA, Kim SH.
    Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.